Seres Therapeutics, INC 8-K filings

Seres Therapeutics announced second quarter 2026 financial results, highlighting positive clinical data for its SER-155 program in immune checkpoint inhibitor-related enterocolitis and detailing significant efforts to reduce operational costs.

Seres Therapeutics has entered into a lease amendment and termination agreement to reduce its facilities footprint and ongoing costs, involving a cash payment and stock issuance.

Seres Therapeutics stockholders approved an amendment to the 2025 Incentive Award Plan, increasing available shares, and ratified auditor appointment at the reconvened annual meeting.

Seres Therapeutics announced encouraging top-line results from an investigator-sponsored trial evaluating SER-155 in patients with immune checkpoint inhibitor-related enterocolitis (irEC).

Seres Therapeutics has amended its Nestlé asset purchase agreement and restructured its office lease to extend its cash runway into Q1 2027.

Seres Therapeutics, Inc. announced the resignation of Dr. Hans-Juergen Woerle from its board of directors, effective May 31, 2026.

Seres Therapeutics reported Q1 2026 financial results, highlighting upcoming clinical readouts for SER-155 and advancing its I&I pipeline, while managing operational expenses and seeking capital.

Seres Therapeutics, Inc. announced the date for its 2026 annual meeting of stockholders and a revised deadline for stockholder proposals.

Seres Therapeutics announced its Q4 and full-year 2025 financial results, highlighting a shift to net income from continuing operations and progress in its inflammatory and immune disease pipeline.

Seres Therapeutics reported third quarter 2025 financial results, including net income from continuing operations, and is finalizing its SER-155 Phase 2 study protocol while actively seeking funding for its advancement.

Seres Therapeutics announced a 25% workforce reduction and cost-cutting measures to extend its cash runway into the second quarter of 2026.

Seres Therapeutics announced second quarter 2025 financial results, a reduced net loss, and active pursuit of capital to advance its lead drug candidate, SER-155, into Phase 2 clinical trials.

Seres Therapeutics, Inc. announced the resignation of its President and CEO, Eric D. Shaff, effective July 31, 2025, and the appointment of Marella Thorell and Thomas J. DesRosier as Co-Chief Executive Officers and Co-Presidents, effective August 1, 2025.

Seres Therapeutics announced its Q1 2025 financial results, highlighting a net income driven by the Nestl payment and progress in advancing its SER-155 program for bloodstream infection prevention.

Seres Therapeutics implemented a 1-for-20 reverse stock split of its common stock, effective April 21, 2025, to increase its stock price and maintain Nasdaq compliance.

Seres Therapeutics' stockholders approved a reverse stock split and the 2025 Incentive Award Plan at the company's annual meeting on April 10, 2025.

Seres Therapeutics announces positive clinical data for SER-155, provides business updates, and reports financial results for Q4 and full year 2024, extending its cash runway into Q1 2026.

Lisa von Moltke, Executive Vice President and Chief Medical Officer of Seres Therapeutics, has announced her resignation, effective March 14, 2025, to take a similar role at another biopharmaceutical company.

Seres Therapeutics expands its Board of Directors and appoints Hans-Juergen Woerle, Chief Medical Officer and Chief Scientific Officer at Nestl Health Science S.A., as a Class III director.

Seres Therapeutics highlights positive Phase 1b results for SER-155 in preventing bloodstream infections and details the financial impact of the VOWST asset sale, extending their cash runway into Q1 2026.

Seres Therapeutics reported positive biomarker data from its SER-155 Phase 1b study, showing improved epithelial barrier integrity and reduced systemic inflammation, and announced a cash runway extended into Q1 2026.

Seres Therapeutics announced positive Phase 1b clinical results for SER-155, a reduction in bloodstream infections, and a strategic focus on its pipeline after the sale of VOWST.

Seres Therapeutics completes the sale of its VOWST business to Nestl Health Science, securing $175M upfront and shifting focus to its novel biotherapeutics platform.

Seres Therapeutics' stockholders have approved the sale of its VOWST business to Nestl Health Science, with the transaction expected to close on September 30, 2024.

Seres Therapeutics reports that its SER-155 therapy significantly reduced bloodstream infections and antibiotic use in patients undergoing stem cell transplants.

Seres Therapeutics has filed a Form 8-K to furnish its historical consolidated financial statements for the fiscal years ended December 31, 2023 and 2022, previously included in its Annual Report on Form 10-K.

Seres Therapeutics reported its Q2 2024 financial results, highlighted by a strategic sale of its VOWST business to Nestle, which is expected to provide a significant cash infusion and extend the company's operational runway.

Seres Therapeutics has agreed to sell its VOWST microbiome therapeutic business to Socit des Produits Nestl S.A. for a total potential consideration of up to $335 million, plus a profit sharing arrangement.

Seres Therapeutics has agreed to sell its VOWST business to Nestl Health Science for a total potential consideration of up to $525 million, including upfront payments, milestone payments, and an equity investment.

Seres Therapeutics announced its first quarter 2024 financial results, highlighting increased VOWST sales and progress in its SER-155 clinical trial.